Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 0 | 1,859 | 40 | 0 | 81 |
| Receivables | N/A | 831 | N/A | N/A | N/A |
| TOTAL | $60 | $2,930 | $97 | $37 | $81 |
| Non-Current Assets | |||||
| Investments And Advances | 5,968 | 0 | 5,935 | 6,240 | 6,192 |
| Other Non-Current Assets | 0 | 11 | 0 | 0 | 0 |
| TOTAL | $5,968 | $11 | $5,935 | $6,240 | $6,192 |
| Total Assets | $6,028 | $2,941 | $6,032 | $6,277 | $6,273 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 644 | 3,153 | 379 | 297 | 313 |
| Accrued Expenses | N/A | 42,762 | N/A | N/A | N/A |
| Other current liabilities | 1,313 | N/A | N/A | N/A | N/A |
| TOTAL | $1,957 | $46,164 | $379 | $297 | $316 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,851 | 548 | 2,451 | 2,354 | 2,181 |
| TOTAL | $2,851 | $548 | $2,451 | $2,354 | $2,181 |
| Total Liabilities | $4,808 | $46,712 | $2,831 | $2,651 | $2,497 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 269 | 269 | 269 | 269 | 272 |
| Common Shares | 3 | 43 | 3 | 3 | 3 |
| Retained earnings | -1,614 | -90,180 | 367 | 493 | 643 |
| TOTAL | $1,220 | $-43,771 | $3,201 | $3,626 | $3,776 |
| Total Liabilities And Equity | $6,028 | $2,941 | $6,032 | $6,277 | $6,273 |